Form 4: Director Cheryl Blanchard Receives Xilio Stock Options

Director Cheryl R. Blanchard was granted 10,000 stock options in Xilio Therapeutics, Inc. as part of a standard equity incentive.

Summary

• Director Cheryl R. Blanchard acquired 10,000 stock options in Xilio Therapeutics, Inc. (XLO).
• The options have an exercise price of $8.40 per share.
• The grant date is April 15, 2026, with an expiration date of April 14, 2036.
• The options vest in three equal annual installments starting April 15, 2027, through April 15, 2029.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• The value of the options is dependent on the future market performance of Xilio Therapeutics common stock.

Future Outlook

The options vest over a three-year period, incentivizing the director's continued service to the company through April 2029.

Management Comments

• The grant is subject to the Reporting Person's continued service to the Issuer through the applicable vesting date.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to ensure board alignment with long-term corporate milestones and clinical development progress.

Comparison to Industry Standards

• The use of three-year vesting schedules for director equity is consistent with standard corporate governance practices for mid-cap and small-cap biotech firms.
• The grant size is typical for independent director compensation packages in the life sciences industry.

Stakeholder Impact

• Shareholders may experience minor dilution if these options are exercised in the future.

Next Steps

• Vesting of the first tranche of options on April 15, 2027.

Key Dates

Keywords

Xilio Therapeutics, XLO, Form 4, Insider Trading, Stock Options, Director Compensation